150 related articles for article (PubMed ID: 21363880)
1. Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer.
Argiris A; Karamouzis MV; Smith R; Kotsakis A; Gibson MK; Lai SY; Kim S; Branstetter BF; Shuai Y; Romkes M; Wang L; Grandis JR; Ferris RL; Johnson JT; Heron DE
Ann Oncol; 2011 Nov; 22(11):2482-2488. PubMed ID: 21363880
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer.
Argiris A; Karamouzis MV; Gooding WE; Branstetter BF; Zhong S; Raez LE; Savvides P; Romkes M
J Clin Oncol; 2011 Mar; 29(9):1140-5. PubMed ID: 21343546
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck.
Villaflor VM; Haraf D; Salama JK; Kocherginsky M; Langerman A; Gomez-Abuin G; Beniwal P; Blair EA; Stenson KM; Portugal L; Seiwert T; Williams RD; Dekker AJ; Witt ME; Vokes EE; Cohen EEW
Ann Oncol; 2011 Nov; 22(11):2501-2507. PubMed ID: 21385883
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck.
Vermorken JB; Licitra L; Stöhlmacher-Williams J; Dietz A; Lopez-Picazo JM; Hamid O; Hossain AM; Chang SC; Gauler TC
Eur J Cancer; 2013 Sep; 49(13):2877-83. PubMed ID: 23726971
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck.
Kuhnt T; Sandner A; Wendt T; Engenhart-Cabillic R; Lammering G; Flentje M; Grabenbauer G; Schreiber A; Pirnasch A; Dunst J
Ann Oncol; 2010 Nov; 21(11):2284-2289. PubMed ID: 20427347
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).
Fury MG; Sherman EJ; Rao SS; Wolden S; Smith-Marrone S; Mueller B; Ng KK; Dutta PR; Gelblum DY; Lee JL; Shen R; Kurz S; Katabi N; Haque S; Lee NY; Pfister DG
Ann Oncol; 2014 Mar; 25(3):689-694. PubMed ID: 24496920
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.
Kim ES; Neubauer M; Cohn A; Schwartzberg L; Garbo L; Caton J; Robert F; Reynolds C; Katz T; Chittoor S; Simms L; Saxman S
Lancet Oncol; 2013 Dec; 14(13):1326-36. PubMed ID: 24231627
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group.
Jalal S; Waterhouse D; Edelman MJ; Nattam S; Ansari R; Koneru K; Clark R; Richards A; Wu J; Yu M; Bottema B; White A; Hanna N
J Thorac Oncol; 2009 Nov; 4(11):1420-4. PubMed ID: 19701110
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407.
Govindan R; Bogart J; Stinchcombe T; Wang X; Hodgson L; Kratzke R; Garst J; Brotherton T; Vokes EE
J Clin Oncol; 2011 Aug; 29(23):3120-5. PubMed ID: 21747084
[TBL] [Abstract][Full Text] [Related]
10. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.
Argiris A; Duffy AG; Kummar S; Simone NL; Arai Y; Kim SW; Rudy SF; Kannabiran VR; Yang X; Jang M; Chen Z; Suksta N; Cooley-Zgela T; Ramanand SG; Ahsan A; Nyati MK; Wright JJ; Van Waes C
Clin Cancer Res; 2011 Sep; 17(17):5755-64. PubMed ID: 21750205
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
Gadgeel SM; Ruckdeschel JC; Patel BB; Wozniak A; Konski A; Valdivieso M; Hackstock D; Chen W; Belzer K; Burger AM; Marquette L; Turrisi A
J Thorac Oncol; 2011 May; 6(5):927-33. PubMed ID: 21415776
[TBL] [Abstract][Full Text] [Related]
12. Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.
Perri F; Muto P; Argenone A; Ionna F; Longo F; Fulciniti F; Sandomenico F; Daponte A; Caponigro F
Oncology; 2013; 84(4):251-4. PubMed ID: 23428719
[TBL] [Abstract][Full Text] [Related]
13. Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer.
Argiris A; Bauman JE; Ohr J; Gooding WE; Heron DE; Duvvuri U; Kubicek GJ; Posluszny DM; Vassilakopoulou M; Kim S; Grandis JR; Johnson JT; Gibson MK; Clump DA; Flaherty JT; Chiosea SI; Branstetter B; Ferris RL
Ann Oncol; 2016 Aug; 27(8):1594-600. PubMed ID: 27177865
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and pemetrexed, cisplatin for locally advanced esophageal squamous cell carcinoma.
Li BS; Gong HY; Huang W; Yi Y; Zhang ZC; Li HS; Wang ZT; Yu JM
Dis Esophagus; 2011 May; 24(4):251-7. PubMed ID: 21073623
[TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Keil F; Selzer E; Berghold A; Reinisch S; Kapp KS; De Vries A; Greil R; Bachtiary B; Tinchon C; Anderhuber W; Burian M; Kasparek AK; Elsäßer W; Kainz H; Riedl R; Kopp M; Kornek G
Eur J Cancer; 2013 Jan; 49(2):352-9. PubMed ID: 22981499
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
[TBL] [Abstract][Full Text] [Related]
17. Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Machiels JP; Kaminsky MC; Keller U; Brümmendorf TH; Goddemeier T; Forssmann U; Delord JP
Invest New Drugs; 2013 Oct; 31(5):1207-16. PubMed ID: 23397499
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck.
Pivot X; Raymond E; Laguerre B; Degardin M; Cals L; Armand JP; Lefebvre JL; Gedouin D; Ripoche V; Kayitalire L; Niyikiza C; Johnson R; Latz J; Schneider M
Br J Cancer; 2001 Sep; 85(5):649-55. PubMed ID: 11531245
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors.
Misset JL; Gamelin E; Campone M; Delaloge S; Latz JE; Bozec L; Fumoleau P
Ann Oncol; 2004 Jul; 15(7):1123-9. PubMed ID: 15205208
[TBL] [Abstract][Full Text] [Related]
20. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
Powrózek T; Kowalski DM; Krawczyk P; Ramlau R; Kucharczyk T; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Dyszkiewicz W; Krzakowski M; Milanowski J
Clin Lung Cancer; 2014 Nov; 15(6):455-65. PubMed ID: 25246386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
